Trials / Terminated
TerminatedNCT01679080
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of Aarhus · Academic / Other
- Sex
- All
- Age
- 22 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the present study is to investigate the effect of treatment of adult OI patients with bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass, fracture risk and quality of life. The investigators will therefore conduct a double blind, placebo controlled trial, taking genotype and previous antiresorptive therapy into account.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid | antiresorptive and calcium and vitamin D |
| DRUG | Teriparatide | anabolic and calcium and vitamin D |
| OTHER | No active treatment | Calcium and vitamin D |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2020-07-01
- Completion
- 2021-06-01
- First posted
- 2012-09-05
- Last updated
- 2021-06-25
Locations
3 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01679080. Inclusion in this directory is not an endorsement.